TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Following a small, open-label pilot study that yielded very promising results of BATD, the current study will consist of a larger, randomized control trial (n=60) that will compare BATD to Supportive Counseling in outcomes of depression, contact with positive reinforcement in the environment, treatment satisfaction, therapeutic alliance, and perceived stigma. In addition, participants' adherence rates to each of the therapies and their maintenance of clinical gains at a 1-month follow-up, will be examined.


Options:
A: Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral activation psychotherapy | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Behavioral activation psychotherapy; Assigned to Arm(s): Behavioral Activation | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual Care
B: Arm Label: Behavioral Activation Treatment for Depression; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for Depression Treatment | Arm Label: Supportive Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Counseling | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for Depression Treatment; Assigned to Arm(s): Behavioral Activation Treatment for Depression | Intervention Type: BEHAVIORAL; Name: Supportive Counseling; Assigned to Arm(s): Supportive Counseling
C: Arm Label: Support Group (Control Group); Type: OTHER; Interventions: Behavioral: Support Group | Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Support Group; Assigned to Arm(s): Support Group (Control Group)
D: Arm Label: 4 face-to-face and smartphone-app; Type: EXPERIMENTAL; Interventions: Behavioral: 4 face-to-face therapy session and a smartphone-app | Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT, treatment as usual | Intervention Type: BEHAVIORAL; Name: 4 face-to-face therapy session and a smartphone-app; Assigned to Arm(s): 4 face-to-face and smartphone-app | Intervention Type: BEHAVIORAL; Name: CBT, treatment as usual; Assigned to Arm(s): TAU

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Brief Summary: The occurrence of bronchiolitis obliterans syndrome (SBO) after allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be a chronic pulmonary graft versus host disease (GVHD) that is associated with significant mortality and morbidity. The reported incidence of SBO varies from 6 to 26% of allogeneic HSC recipients and is usually diagnosed within 2 years after transplantation. The diagnosis of SBO relies on the occurrence of a new airflow obstruction identified during pulmonary function testing, and the definition differs between studies. Currently, no curative immunosuppressive treatment is available, and recent data suggest that the use of these treatments, especially corticosteroids, should be limited because of their toxicity. The impairment of lung function parameters is likely caused by fibrous small airway lesions. Few data on the pathogenesis of SBO after allogeneic HSCT are available. Several hypotheses are based on the occurrence of SBO during chronic graft rejection after lung transplantation, which shares many clinical and histopathological similarities with SBO after allogeneic HSCT. One hypothesis is that the first step leading to SBO is lung epithelium injury. SBO is then identified as an alloimmune reaction with only one clearly identified risk factor: extrathoracic chronic GVHD. Due to their anti-inflammatory and immunomodulatory properties, recent data suggest that low-dose macrolides may be effective at preventing SBO after lung transplants. This well-tolerated treatment may be useful for preventing SBO after allogeneic HSCT.

The objective of this Phase 3 multicentre randomized, double-blinded, clinical trial is to evaluate the efficacy of azithromycin in preventing BO syndrome after allogeneic HSCT in patients with malignant hematological diseases.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Roxithromycin; Assigned to Arm(s): N/A
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Azithromycine; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).


Options:
A: Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CP-690,550 5 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP690,550 | Arm Label: CP-690,550 10 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator | Intervention Type: DRUG; Name: CP690,550; Assigned to Arm(s): CP-690,550 5 mg Arm | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg Arm
B: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo BID
C: Arm Label: Active 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 25 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 25 mg once daily | Arm Label: JNJ-54781532 75 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg once daily | Arm Label: JNJ-54781532 150 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 75 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg twice daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-54781532 25 mg once daily; Assigned to Arm(s): JNJ-54781532 25 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 75 mg once daily; Assigned to Arm(s): JNJ-54781532 75 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 150 mg once daily; Assigned to Arm(s): JNJ-54781532 150 mg once daily, Placebo | Intervention Type: DRUG; Name: JNJ-54781532 75 mg twice daily; Assigned to Arm(s): JNJ-54781532 75 mg twice daily

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Brief Summary: This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.


Options:
A: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: LX4211 | Arm Label: LX4211 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LX4211 Placebo | Intervention Type: DRUG; Name: LX4211; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: LX4211 Placebo; Assigned to Arm(s): LX4211 Placebo
B: Arm Label: Insulin degludec (IDeg); Type: EXPERIMENTAL; Interventions: Drug: insulin degludec | Arm Label: Insulin glargine (IGlar); Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin degludec (IDeg) | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): Insulin glargine (IGlar)
C: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin
D: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.


Options:
A: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
B: Arm Label: Tafamidis - 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Tafamidis - 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Tafamidis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 20 mg | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Tafamidis - 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1
D: Arm Label: patisiran (ALN-TTR02); Type: ACTIVE_COMPARATOR; Interventions: Drug: patisiran (ALN-TTR02) | Arm Label: Sterile Normal Saline (0.9% NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile Normal Saline (0.9% NaCl) | Intervention Type: DRUG; Name: patisiran (ALN-TTR02); Assigned to Arm(s): patisiran (ALN-TTR02) | Intervention Type: DRUG; Name: Sterile Normal Saline (0.9% NaCl); Assigned to Arm(s): Sterile Normal Saline (0.9% NaCl)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)
Brief Summary: In this feasibility trial, the investigators will compare participants treated with montelukast and hydroxyurea to those treated with placebo and hydroxyurea for a total of 8 weeks.


Options:
A: Arm Label: Montelukast added to Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Montelukast added to Hydroxyurea | Arm Label: Placebo added to Hydroxyurea; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo added to Hydroxyurea | Intervention Type: DRUG; Name: Montelukast added to Hydroxyurea; Assigned to Arm(s): Montelukast added to Hydroxyurea | Intervention Type: DRUG; Name: Placebo added to Hydroxyurea; Assigned to Arm(s): Placebo added to Hydroxyurea
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1
C: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Alternative Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Alternative Arm, Standard Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II
Brief Summary: BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of this study is to assess the safety and clinical performance of the drug eluting absorbable metal scaffold (DREAMS 2nd Generation).


Options:
A: Arm Label: Drug Eluting Absorbable Metal Scaffold; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention (DREAMS) stenting | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention (DREAMS) stenting; Assigned to Arm(s): Drug Eluting Absorbable Metal Scaffold
B: Arm Label: Bare metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Percutaneous coronary intervention (PCI) | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: Percutaneous coronary intervention (PCI) | Intervention Type: DEVICE; Name: Percutaneous coronary intervention (PCI); Assigned to Arm(s): Bare metal stent | Intervention Type: DEVICE; Name: Percutaneous coronary intervention (PCI); Assigned to Arm(s): Drug eluting stent
C: Arm Label: bare metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent implantation | Arm Label: Endeavor sprint stent; Type: EXPERIMENTAL; Interventions: Device: zotarolimus eluting stent | Intervention Type: DEVICE; Name: Bare metal stent implantation; Assigned to Arm(s): bare metal stent | Intervention Type: DEVICE; Name: zotarolimus eluting stent; Assigned to Arm(s): Endeavor sprint stent
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Biolimus eluted from an erodable stent coating (Biomatrix) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent (Gazelle) | Intervention Type: DEVICE; Name: Biolimus eluted from an erodable stent coating (Biomatrix); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent (Gazelle); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trials for Elderly Patients With Multiple Disease
Brief Summary: The CHROMED project focuses its investigation on the applicability of an integrated solution for a pathological condition which: a) is very prevalent in ageing patients and b) severely impairs quality of life: COPD with other typical comorbidities such as congestive heart failure and sleep disordered breathing. A specific ICT platform in combination with a set of innovative devices will be used to collect and process useful clinical data at the patient's home and used to optimize their medical treatment. To evaluate the impact of this solution, an international multi-centric randomized control trial will be implemented in five European regions: United Kingdom, Sweden, Estonia, Spain and Slovenia, representing different social and organizational contexts in Europe.


Options:
A: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Oxygen | Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen
C: Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Device: CHROMED monitoring system | Intervention Type: DEVICE; Name: CHROMED monitoring system; Assigned to Arm(s): Interventional
D: Arm Label: Tiotropium low; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium low | Arm Label: Tiotropium medium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium medium | Arm Label: Tiotropium high; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium high | Arm Label: Tiotropium 18mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18mcg | Arm Label: Tiotropium placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tiotropium placebo | Intervention Type: DRUG; Name: Tiotropium medium; Assigned to Arm(s): Tiotropium medium | Intervention Type: DRUG; Name: Tiotropium low; Assigned to Arm(s): Tiotropium low | Intervention Type: DRUG; Name: Tiotropium high; Assigned to Arm(s): Tiotropium high | Intervention Type: DRUG; Name: Tiotropium 18mcg; Assigned to Arm(s): Tiotropium 18mcg | Intervention Type: DRUG; Name: Tiotropium placebo; Assigned to Arm(s): Tiotropium placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Launching a Salt Substitute to Reduce Blood Pressure at the Population Level - Peru
Brief Summary: This protocol aims to implement, using a stepped wedge trial design, a population-level intervention to replace high-sodium salt for a salt substitute (low-sodium, high-potassium salt) to reduce blood pressure levels among adults aged 18 years and over of the semi-urban area of Tumbes.

We hypothesize that participants aged 18 years and over from villages receiving a salt substitute will have lower blood pressure compared to control villages.


Options:
A: Arm Label: Blood pressure-measurement; Type: EXPERIMENTAL; Interventions: Device: cuff device (Omron HBP-1300-E Pro), Device: iPhone 4s | Intervention Type: DEVICE; Name: cuff device (Omron HBP-1300-E Pro); Assigned to Arm(s): Blood pressure-measurement | Intervention Type: DEVICE; Name: iPhone 4s; Assigned to Arm(s): Blood pressure-measurement
B: Arm Label: Normal Salt; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regular Salt | Arm Label: Salt Substitute; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Salt Substitute | Intervention Type: DIETARY_SUPPLEMENT; Name: Regular Salt; Assigned to Arm(s): Normal Salt | Intervention Type: DIETARY_SUPPLEMENT; Name: Salt Substitute; Assigned to Arm(s): Salt Substitute
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reduced-sodium added-potassium salt substitute; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary sodium reduction | Intervention Type: BEHAVIORAL; Name: Dietary sodium reduction; Assigned to Arm(s): Reduced-sodium added-potassium salt substitute
D: Arm Label: Salt substitute; Type: EXPERIMENTAL; Interventions: Other: Salt substitute | Intervention Type: OTHER; Name: Salt substitute; Assigned to Arm(s): Salt substitute

Answer: D